MEDICO REMEDIES LTD.

A WHO-GMP, ISO 9001-2015 & GOVT. RECOGNISED STAR EXPORT HOUSE

Manufacturers of Pharmaceutical Formulations

CIN L24230MH1994PLC077187
GSTIN- 27AABCM8349L1ZY

Regd. Office : 1105/1106, Hubtown Solaris, N. S. Phadke Marg, Opp. Teligali, Andheri - East, Mumbai - 400 069. • Tel. : +91-22-2682 1054 / 1055 / 2683 7116
Email : medicoremedies@yahoo.com • info@medicoremedies.com • **Website :** www.medicoremediesindia.com • www.medicoremediesindia.net • www.tabletandcapsules.

Date: 10th February, 2023

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai – 400 001 **Scrip Code: 540937**	**National Stock Exchange of India Limited** 5th Floor, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai-400051 **Symbol: MEDICO**

Dear Sir/Madam,

Re.: Outcome of Board Meeting held today

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 10th February, 2023 has, inter alia considered and approved the Quarterly Unaudited Standalone Financial Results of the Company for the Quarter and Nine Months ended 31st December, 2022 along with the Limited Review Report thereon. (enclosed)

We wish to inform you that the Board Meeting commenced today at 2.00 P.M and concluded at 5: 15 P.M

Kindly take the same on record.

Thanking You,

FOR MEDICO REMEDIES LIMITED

HARESH
KAPURLAL
MEHTA

Digitally signed by HARESH KAPURLAL MEHTA
DN: c=IN, st=Maharashtra,
2.5.4.20=d9fde21b6be55c54cae075f89a65def9ba6c9c81be76c1e7600439776ed15913,
postalCode=400049, street=Mumbai,
pseudonym=ec3068b909b8f8ac2e5c69b505045deb,
serialNumber=e0132295817082838a422934c4242acc34f73565616aef234b56c49b7781a2be,
o=Personal, cn=HARESH KAPURLAL MEHTA
Date: 2023.02.10 17:18:01 +05'30'

HARESH KAPURLAL MEHTA
CHAIRMAN & WHOLETIME DIRECTOR
DIN: 01080289

Encl: As above

DIES LIMITED

1994PLC077187

Results for the Quarter Ended on Dec 31, 2022

(Rs. in lakhs)

rter ended		For the Period Ended		For the Year Ended
-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
4,046.22	3,013.20	11,244.59	8,874.32	12,102.09
155.04	23.26	400.96	129.29	202.90
4,201.27	3,036.46	**11,645.55**	**9,003.61**	**12,305.00**
2,930.88	2,169.03	7,940.26	6,148.15	8,467.20
233.42	49.20	557.31	226.62	288.08
-173.80	-140.13	-40.15	81.00	-26.20
136.50	209.56	441.41	452.20	541.07
17.42	20.44	54.10	53.32	66.22
66.42	43.50	199.45	133.66	221.84
604.53	533.68	1,710.60	1,495.04	2,098.49
3,815.38	**2,885.27**	**10,862.97**	**8,589.98**	**11,656.70**
385.89	**151.19**	**782.58**	**413.63**	**648.30**
82.42	44.00	205.72	120.00	179.47
16.65	5.70	29.28	8.53	-12.37
99.07	**49.70**	**235.00**	**128.53**	**167.10**
286.82	**101.48**	**547.57**	**285.09**	**481.20**
			-	-
-1.04	-0.95	-3.03	-2.85	-3.80
0.26	0.24	0.76	0.72	0.96
-0.78	**-0.71**	**-2.27**	**-2.13**	**-2.84**
286.04	**100.77**	**545.30**	**282.96**	**478.36**
165.97	165.97	165.97	165.97	165.97
				1,997.78
1.73	**0.61**	**3.30**	**1.72**	**2.90**
1.73	**0.61**	**3.30**	**1.72**	**2.90**

Hhmehta

Notes to Financial Results

1. The Company was listed in SME segment of BSE Ltd. as on 31st March, 2022 and migrated to the Main Board on 26th May 2022. Accordingly, the Company has adopted Indian Accounting Standard ("Ind AS"), as notified under section 133 of the Companies Act, 2013 ("the Act") which is applicable to the Company from 1st April, 2022.

2. The Company has first time adopted Indian Accounting Standards ("Ind AS") from 1st April, 2022 and accordingly these results have been prepared in accordance with the recognition and measurement principles laid down in the Ind AS 34, Interim Financial Reporting prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting pronouncements generally accepted in India.

3. The Company has adopted first time Indian Accounting Standard ("Ind AS"), accordingly the Company had prepared comparative figures of quarter & nine months ended 31st December, 2021 as given above by the management after exercising necessary due diligence to ensure financial results reflects true and fair view of Company's affairs in Indian Accounting Standards ("IndAS").

4. The Company's management, pursuant to Ind AS 108 - Operating Segments, has concluded that the Company has only one reportable segment i.e. "Pharmaceuticals". Accordingly, no separate disclosures of segment information have been made.

5. IGAAP and IND-AS Reconciliation:

EQUITY RECONCILIATION Figures +/Dr & (-)/Cr

Particulars	31.03.2021	FY 2021-22	FY 2022-23 (Q1)	FY 2022-23 (Q2)	FY 2022-23 (Q3)
Reserves as per IGAAP	**12,49,91,114**	**12,49,91,114**	**17,38,81,118**	**17,77,90,675**	**20,31,57,668**
Provision of ECL adjusted in [illegible] Equity / Opening IndAS Adj	(63,65,151)	(63,65,151)	(71,35,278)	(74,65,004)	(41,49,782)
Ind AS Adjustments for the period		(7,70,127)	(3,29,726)	33,15,221	(1,58,659)
Total Ind AS impact	**(63,65,151)**	**(71,35,278)**	**(74,65,004)**	**(41,49,782)**	**(43,08,441)**
Profit as per IGAAP		**4,88,90,004**	**39,09,557**	**2,53,66,993**	**2,25,75,787**
Reserves as per IndAS	**11,86,25,963**	**16,67,45,840**	**17,03,25,671**	**19,90,07,886**	**22,14,25,014**

OTHER EQUITY (SOCI)

Particulars	Reserve and Surplus		Other items of Other Comprehensive	Total Equity
	Securities Premium Reserve	Retained Earnings		
Balance at April 1, 2022	**3,33,16,388**	**16,67,45,840**	**-2,84,318**	**19,97,77,910**
				-
Profit for the year	-	35,79,831	-	35,79,831
Total comprehensive income for the period	-	-	(71,080)	(71,080)
				-
Balance at June 30, 2022	**3,33,16,388**	**17,03,25,671**	**(3,55,398)**	**20,32,86,661**
		-	-	
Profit for the year	-	2,86,82,214	-	2,86,82,214
Total comprehensive income for the period	-	-	(78,188)	(78,188)
Balance at Sep 30, 2022	**3,33,16,388**	**19,90,07,886**	**(4,33,585)**	**23,18,90,688**
Profit for the year	-	2,24,95,315	-	2,24,95,315
Total comprehensive income for the period	-	-	(78,187)	(78,187)
Balance at Dec 31, 2022	**3,33,16,388**	**22,15,03,200**	**(5,11,772)**	**25,43,07,816**

6. The Audit Committee has reviewed, and the Board of Directors has approved the above results and its release at their respective meetings held on 10th February, 2023. The Statutory Auditors of the Company have carried out Limited Review of the aforesaid results.

MEDICO REMEDIES LTD. MUMBAI

Hmehta Hh mehta